Enanta Pharmaceuticals Reports Q3 Results for Quarter Ended June 30, 2026

What Happened

• Enanta Pharmaceuticals, Inc. announced and filed an 8-K on August 10, 2026, reporting its financial results for the fiscal quarter ended June 30, 2026. The company furnished a press release with those results (Exhibit 99.1) as part of the filing.

Key Details

• Filing date: August 10, 2026 (Form 8-K, Item 2.02).
• Reporting period: fiscal quarter ended June 30, 2026.
• Press release reporting the quarterly results is furnished and incorporated by reference as Exhibit 99.1.
• The 8-K was signed on behalf of Enanta by Jay R. Luly, Ph.D., President and Chief Executive Officer; the filing also includes the Inline XBRL cover page (Exhibit 104).

Why It Matters

• This 8-K provides investors with Enanta’s latest quarterly results and an official press release; these materials typically include key metrics such as revenue, earnings or operating updates that can affect the stock. Retail investors should read the furnished press release (Exhibit 99.1) and related SEC filings for the specific financial figures and any commentary on business trends or guidance.